Progression of periodontal disease in HIV seropositive patients.
Data from cross-sectional studies suggest that periodontitis in HIV-infected patients is a more destructive form of disease in contrast to the slowly progressing form of adult periodontitis in the general population. We studied prospectively over an 18-month period 30 HIV infected, but asymptomatic, patients and compared the rate of periodontal attachment loss with that of a healthy control group (n = 10) matched for age and plaque index. Every 6 months, each subject was assessed for their clinical status by a physician and CD4+ cell count determined. The proliferative response of peripheral blood lymphocytes was determined by in vitro cultures with PHA and Con A. The periodontal health status was assessed by scoring with plaque index (PI), gingival index (GI), and periodontal disease index (PDI). The control subjects were assessed for periodontal status only. Of the 30 HIV-positive patients whose data were analyzed 14 received Zidovudine (AZT) while the remaining 16 did not. There was no correlation between any clinical parameter measured and periodontal status as determined by PI or GI. However, a significant difference in the change of periodontal disease index (PDI) was observed between the HIV-infected and control groups (P = 0.005). We concluded that HIV-infected patients with pre-existing periodontitis tend to experience a greater rate of attachment loss over time compared with controls.
Yeung
S C
SC
Department of Preventive Dentistry, University of Sydney, Westmead Hospital, Australia.
Stewart
G J
GJ
Cooper
D A
DA
Sindhusake
D
D
D000328:Adult; D016516:CD4-CD8 Ratio; D016022:Case-Control Studies; D015331:Cohort Studies; D003208:Concanavalin A / Q000494:pharmacology; D003774:Dental Plaque Index; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006679:HIV Seropositivity; D006801:Humans; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D010512:Periodontal Index; D010518:Periodontitis / Q000150:complications* / Q000276:immunology / Q000473:pathology*; D010835:Phytohemagglutinins / Q000494:pharmacology; D012044:Regression Analysis; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use
D010835:Phytohemagglutinins; D003208:Concanavalin A; D015215:Zidovudine